Avanos Medical, Inc.
Main Filters
Avanos Medical, Inc.
| Avanos | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| 181A466 | 0 | - | ||
| 181A467 | 0 | - | ||
| 181A468 | 0 | - | ||
| 181A469 | 0 | - | ||
| 181A470 | 0 | - | ||
| 181A471 | 0 | - | ||
| 181A472 | 0 | - | ||
| 181A473 | 0 | - | ||
| 181A474 | 0 | - | ||
| 181A475 | 0 | - | ||
| 181A476 | 0 | - | ||
| 181A477 | 0 | - | ||
| 182A264 | 0 | - | ||
| 182A265 | 0 | - | ||
| 182A266 | 0 | - | ||
| 182A267 | 0 | - | ||
| 195-4J | 0 | - | ||
| 196-4J | 0 | - | ||
| 197-4J | 0 | - | ||
| 198-4J | 0 | - | ||
| 2155-4J | 0 | - | ||
| 21559-4J | 0 | - | ||
| 216069-4J | 0 | - | ||
| 21609-4J | 0 | - | ||
| 2208A055 | 0 | - | ||
| 2208A216 | 0 | - | ||
| 22109-4J | 0 | - | ||
| 225158 | 0 | - | ||
| 50653-0006-01 | 0 | - | ||
| 50653-0006-04 | 0 | - | ||
| 8224 | 0 | - | ||
| 8248 | 0 | - | ||
| CRA-QPU-1-L | 0 | - | ||
| CRA-QPU-1-R | 0 | - | ||
| CRA-TBK-1 | 0 | - | ||
| CRA-TBK-2 | 0 | - | ||
| CRG-ADVANCED-L | 0 | - | ||
| CRG-BASIC-L | 0 | - | ||
| CRX-BAY-CRP | 0 | - | ||
| CRX-BAY-MCRF | 0 | - | ||
| MCKA3-17-150-4 | 0 | - | ||
| MCKA3-17-50-2 | 0 | - | ||
| MCKA3-17-75-2 | 0 | - | ||
| PMG-230 | 0 | - | ||
| PMP-18-145 | 0 | - | ||
| PMX-BAY-19-14 | 0 | - | ||
| PMX-BAY-BAY | 0 | - | ||
| PMX-BAY-MRF | 0 | - | ||
| TDX-PMG-PPU | 0 | - | ||
| TDX-Y-TSW-TDP2 | 0 | - | ||
6,175 Results
Results Per Page
- 50
- 100
- 250
Catalog #
AvailableQty
Starting At
Name
Company Name
Description
0
-
TriVisc™ sodium hyaluronate
Avanos
TriVisc™ 850 sodium hyaluronate (P160057) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. TriVisc is a sterile, viscoelastic, non-pyrogenic solution (pH of 6.8-7.8) of highly purified, high molecular weight hyaluronic acid (HA) with an average molecular weight of 850,000 daltons and a range of 620,000 – 1,170,000 daltons). The HA is a polymer of repeating disaccharide units of glucuronic acid and N-acetyl-glucosamine derived from a bacterial fermentation process. TriVisc is supplied in a prefilled syringe containing 25 mg of HA in 2.5 mL of physiological saline solution (1% solution).
0
-
GenVisc® 850 sodium hyaluronate
Avanos
GenVisc® 850 sodium hyaluronate (P140005) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. GenVisc 850 is a sterile, viscoelastic, non-pyrogenic solution (pH of 6.8-7.8) of highly purified, high molecular weight hyaluronic acid (HA) with an average molecular weight of 850,000 daltons and a range of 620,000 – 1,170,000 daltons). The HA is a polymer of repeating disaccharide units of glucuronic acid and N-acetyl-glucosamine derived from a bacterial fermentation process. GenVisc 850 is supplied in a prefilled syringe containing 25 mg of HA in 2.5 mL of physiological saline solution (1% solution).
